Skip to content

Research on the effect of oral rivaroxaban on intestinal flora and its correlation with gastrointestinal bleeding

Research on the effect of oral rivaroxaban on intestinal flora and its correlation with gastrointestinal bleeding

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300075805
Enrollment
Unknown
Registered
2023-09-15
Start date
2022-09-26
Completion date
Unknown
Last updated
2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation

Interventions

Case series:N/A

Sponsors

Suining Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1) age =45 years, =85 years; 2) any gender; 3) meet non-valvular AF anticoagulation criteria: CHA2DS2-VASC score for men =1, and for women=2 ; 4) no digestive system cancer or other systemic malignancy; 5) no history of digestive tract operation ; 6) no use of antibiotics or probiotics in the last 3 months; 7) no use of proton pump inhibitors(PPIs), or H2 receptor antagonists in the last 3 months;(8) No concomitant aspirin; (9) No history of psychiatric or genetic disorders; (10) Voluntarily accept and comply with the study proposal,tolerate relevant tests, and can complete the questionnaire independently under the guidance of the investigator, and accept the review and clinical follow-up on time.

Exclusion criteria

Exclusion criteria: 1) age 85 years; 2) valvular AF; 3) patients who were on warfarin and are changing to NOAC; 4) contraindication to anticoagulation; 5) any digestive system cancer or other systemic malignancy; 6) history of digestive tract operation; 7) use of antibiotics or probiotics in the last 3 months; 8) use of proton pump inhibitors or H2 receptor antagonists in the last 3 months; 9) need for concomitant aspirin; 10) history of psychiatric or genetic disorders; 11) patients who do not wish to participate in this study.

Design outcomes

Primary

MeasureTime frame
Flora;

Countries

China

Contacts

Public ContactHe Suyu

Suining Central Hospital

hesuyu2009@163.com+86 180 0825 8565

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026